ArticleKidney international reports2020
Spondyloarthritis-Associated IgA Nephropathy.
Article in Kidney international reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Association between systemic inflammation-immune index and comorbidities in patients with ankylosing spondylitis: a cross-sectional study.Clinical rheumatology · 2026Article
- Renal involvement in ankylosing spondylitis: a retrospective, population-based cohort study using data from the TriNetX Global Network.RMD open · 2026Article
- Renal involvement in different subtypes of children with juvenile idiopathic arthritis: results from a single-center cohort.Clinical rheumatology · 2026Article
- A multicenter explainable machine learning analysis of autoimmune disease comorbidity in ankylosing spondylitis.Frontiers in immunology · 2026Article
- Metabolomics in spondylarthritis.BMC rheumatology · 2025Article
- Prevalence and Pathogenetic Mechanisms of Chronic Kidney Disease in Autoimmune-Mediated Systemic Diseases.Journal of clinical medicine research · 2025Review
- IgA vasculitis induced by tumor necrosis factor-α antagonists: clinical features, diagnosis and management.Archives of dermatological research · 2025Article
- Acute Kidney Injury in Autoimmune-Mediated Rheumatic Diseases.Journal of clinical medicine research · 2025Review
- Incidence rate of and risk factors for glomerulonephritis in patients with axial spondyloarthritis: a nationwide population-based study.Therapeutic advances in musculoskeletal disease · 2025Article
- Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement.BMC nephrology · 2023Article
- IgA nephropathy.Nature reviews. Disease primers · 2023Review
- Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis.Frontiers in immunology · 2022Article
- Matrix Metalloproteinases and Arterial Hypertension: Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations.Biomolecules · 2021Review
- Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature.Biologics : targets & therapy · 2021Review
- Toward a Clearer Picture of IgA Nephropathy in Spondyloarthritis.Kidney international reports · 2020Article
- Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review.Clinical medicine insights. Case reports · 2020Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIgA nephropathy (IgAN) can be associated with spondyloarthritis (SpA). The course of SpA-associated IgAN remains largely unknown due to the absence of large cohorts.
methodsThis retrospective study included patients with biopsy-proven IgAN and definite SpA. Kidney biopsies were centrally examined and scored according to the IgAN Oxford Classification. Thirty-two patients fulfilled the inclusion criteria, with a male:female ratio of 9:1 and median age of 27 and 37 years at SpA and IgAN diagnosis, respectively. HLA-B27 was positive in 90% of cases, and most patients (60%) presented with ankylosing spondylitis. The mean baseline estimated glomerular filtration rate (eGFR) was 84 ± 26 ml/min per 1.73 m
resultsRenal biopsy revealed frequent presence of crescents (33%) and interstitial inflammation (18%). Despite almost constant use of renin-angiotensin system inhibitors, combined with steroids in 13 of 32 patients, renal outcome was particularly poor. After a median follow-up of 5.9 years, 4 patients (12.5%) reached end-stage renal disease and 41% of patients experienced a >50% decrease of eGFR. The mean annual eGFR decline rate was -4.3 ± 6.7 ml/min per 1.73 m
conclusionSpA-associated IgAN is associated with a poor renal outcome, despite frequent use of steroids. Tumor necrosis factor (TNF)-α blockade did not appear to influence the rate of eGFR decline in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.